Navigation Links
Cell therapy shows remarkable ability to eradicate cancer in clinical study
Date:2/19/2014

NEW YORK, February 19, 2014 Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.

"These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies," said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study's senior authors. "Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer."

Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.

In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were "reeducated" to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.

Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.

A History of Scientific Achievements for Cell-Based Therapies

Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body's own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body's own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.

"Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients," said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study's senior authors. "It's extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up."

In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.

Results Demonstrate Potential of New Therapy

In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation the standard of care and the only curative option for B-ALL patients following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.

The study also provides guidelines for managing side effects of cell therapy, which can include severe flu-like symptoms such as fever, muscle pain, low blood pressure, and difficulty breathing, referred to as cytokine release syndrome. The researchers developed diagnostic criteria and a laboratory test that can identify which patients are at greater risk for developing this syndrome.

Additional studies to determine whether cell therapy can be applied to other types of cancer are already underway, and studies to test whether B-ALL patients would benefit from receiving targeted immunotherapy as frontline treatment are being planned.


'/>"/>

Contact: Andrea Baird
bairda@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Therapy exploits addiction of leukemia cells
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. 19th century therapy for Parkinsons disease may help patients today
10. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... FL (PRWEB) , ... May 06, 2016 , ... ... will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery ... the vision of becoming a leader in optimized drug discovery through innovative cellular ...
(Date:5/6/2016)... ... , ... Online HR/benefits platforms offer a range of benefits functions to employers ... health plans. “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans ... will offer an accurate picture of online benefits today, and the possible risks and ...
(Date:5/6/2016)... ... 06, 2016 , ... Canadian author Mark Black is a speaker, author, and life ... around the world … with the help of his publisher Strategic Book Group and its ... in a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning ... and operated for over 35 years. Maintaining core values of exceptional customer service, quality ... and made them a leading name in San Diego plumbing, and other services including ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of Military ... corporate training, and the National Military Family Association, a nonprofit that works to ... second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship by ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016  Compass Diversified Holdings (NYSE: ... an owner of leading middle market businesses, announced today ... March 31, 2016. First Quarter 2016 Highlights ... Reinvestment ("CAD" or "Cash Flow") of $13.6 million for ... loss of $15.0 million for the first quarter of ...
(Date:5/4/2016)... 4, 2016 According to market research ... Demand Forecast to 2022 - Industry Insights by Slice Type ... and Others)" by P&S Market Research, the global computed ... and it is expected to grow at a CAGR of ... type segment is expected to witness the faster growth, CAGR ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology: